Ionis Pharmaceuticals (IONS) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 68.4% versus a loss of 38.1%. Over five years, JAZZ leads with a +64.3% price change compared with +23.4% for IONS. Jazz Pharmaceuticals is the larger company by market cap ($14.44 billion vs $7.20 billion), about 2.0 times the size, while Ionis Pharmaceuticals is growing revenue faster (+33.8% vs +4.9%).
Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | JAZZ |
|---|---|---|
| Share price | $43.30 | $222.45 |
| Market cap | $7.20B | $14.44B |
| 1-day change | -1.95% | -3.78% |
| YTD return | -45.27% | +35.99% |
| 1-year return | -38.11% | +68.36% |
| 5-year return | +23.36% | +64.31% |
| P/E ratio (TTM) | — | 15.25 |
| Forward P/E | — | 8.58 |
| EPS (TTM) | $-3.48 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $4.27B |
| Revenue growth (YoY) | +33.83% | +4.88% |
| Net income (latest FY) | $-381.39M | $-356.15M |
| Gross margin | 98.31% | — |
| Operating margin | -40.45% | -10.08% |
| Net margin | -40.41% | -8.35% |
| 52-week high | $86.74 | $266.38 |
| 52-week low | $42.63 | $128.80 |
| Distance from 52-week high | -50.08% | -16.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +93.16% | +32.39% |
| Average volume | 3.78M | 850.55K |
| Shares outstanding | 166.18M | 64.91M |
| Employees | 1,480 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Jazz Pharmaceuticals is about 2.0 times larger than Ionis Pharmaceuticals by market value ($14.44B vs $7.20B).
- JAZZ has outperformed IONS by 106.5 percentage points over the past year.
- Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -40.4 cents for Ionis Pharmaceuticals.
- Ionis Pharmaceuticals grew revenue faster in its latest fiscal year (+33.83% vs +4.88%).
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
IONS vs JAZZ FAQ
Which is bigger, Ionis Pharmaceuticals or Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.44B compared with $7.20B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, IONS or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with -38.11% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.